NEW YORK (GenomeWeb News) – Illumina said today that the Broad Institute of MIT and Harvard has purchased 30 of the company's Genome Analyzers, increasing the institute's total installed base of Illumina systems to 89.
Robert Nicol, director of sequencing operations at Broad, said in a statement that the institute purchased the additional instruments to ramp up its sequencing capabilities in whole genome, whole exome, and whole transcriptome analysis.
"We are happy with the technology’s accuracy, ease of use, and scalability, as well as continued system improvements that have recently enabled us to generate multiple runs with more than 50 gigabases of high-quality sequence data," Nicol said.
Financial terms of the deal were not disclosed.
In addition, Illumina today reaffirmed its revenue guidance of a minimum of $165 million for the fourth quarter of 2009.
Last week, Illumina reported that its third-quarter revenues rose 5 percent. However, the company's Q3 revenues were about $4 million below the low end of its guidance and missed analysts' consensus estimate for the quarter, which the company blamed on a sequencing reagent quality issue.